180 Life Sciences Corp - ATNF STOCK NEWS

180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of its registered direct offering, selling 1,570,680 shares of common stock and warrants, generating approximately $3 million in gross proceeds. The shares were priced at $1.91 each, with warrants allowing purchase at $1.78. The net proceeds will fund research and development expenses, including a marketing authorization application.

A.G.P./Alliance Global Partners acted as the placement agent. The offering is based on an effective shelf registration statement with the SEC filed previously. Additionally, existing warrants for 2,878,032 shares will be amended to lower the exercise price to $1.78 and extend the expiration.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a definitive agreement for a registered direct offering to sell 1,570,680 shares of common stock at a price of $1.91 each, alongside warrants to purchase the same amount at an exercise price of $1.78. The total gross proceeds from this offering are expected to be around $3 million, aimed at funding research, development, and corporate expenses. The offering is set to close on or around April 10, 2023. As part of this transaction, existing warrants for 2,878,032 shares will also be amended to lower the exercise price to $1.78 and extend the expiration to five and a half years.

Elicit Plant, a biotechnology firm focused on enhancing crop resilience to water stress, has appointed Pam Marrone as Chairwoman of the Board and Johan de Saegher as Independent Board Member. Marrone brings over 30 years of experience in agricultural biologicals, having previously led Marrone Bio Innovations and AgraQuest. De Saegher has extensive experience in crop protection, including leadership roles in Belchim Crop Protection. The company aims to leverage their expertise as it expands into new markets and enhances its product portfolio, particularly utilizing its innovative phytosterol technology to improve crop yields amidst climate challenges.

180 Life Sciences Corp. (NASDAQ: ATNF) announced that Professor Jagdeep Nanchahal will present at the Gordon Research Conference on "Physiological and Disease Relevance and Underlying Molecular Properties of Collagens" from July 9-14, 2023. Nanchahal's research focuses on Dupuytren’s disease, highlighting tumor necrosis factor (TNF) as a potential treatment target. Following a successful phase 2a trial, the company is advancing to a phase 2b trial that met primary and secondary endpoints with statistical significance. CEO Dr. James Woody emphasized the prestige of the Gordon Research Conferences in advancing scientific discussions.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a Notice of Allowance from the USPTO for a patent application related to treating Dupuytren’s disease. The application includes claims for a citrate-free formulation of adalimumab, administered via a pre-filled syringe every three months for early-stage patients. The anticipated patent, expected to issue soon, will expire no earlier than 2037. This development supports the company's expansion into the treatment of fibrotic disorders. 180 Life Sciences’ patent portfolio will grow to 12 issued patents and 12 pending applications in the U.S. upon patent issuance, enhancing its market position.

180 Life Sciences Corp. (NASDAQ: ATNF) has announced the closure of participant recruitment for the Anti-Freaze-F trial, designed to investigate the effects of anti-TNF (Adalimumab) injections on early-stage frozen shoulder pain. Initially, 84 participants were targeted, but only nine were enrolled due to challenges in recruitment exacerbated by COVID-19. The trial, run by the University of Oxford, faced difficulties due to NHS backlogs. While the trial is closed for new recruits, current participants will continue with their treatments. Management acknowledges the obstacles and may consider conducting future trials in countries with more accessible health systems.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a review titled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery (European Volume). The review, authored by Professor Jagdeep Nanchahal, outlines limitations of current treatments for late-stage Dupuytren’s disease and highlights the efficacy of adalimumab in early-stage cases. A phase 2a and phase 2b trial showed positive results, with significant reductions in nodule hardness and size. CEO Dr. James Woody expressed optimism about advancing anti-TNF treatments for early-stage patients.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its engagement of Kinexum to aid in the submission of a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), seeking a Conditional Marketing Authorisation (CMA). The company estimates spending approximately $900,000 to $1,000,000 over the next three quarters for this initiative. This move reflects the company’s ongoing commitment to address unmet medical needs through innovative clinical programs.

180 Life Sciences Corp. (NASDAQ: ATNF) announced on January 4, 2023, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company received a letter confirming that its common stock's closing bid price remained at or above $1.00 per share for 10 consecutive business days. This compliance is crucial for maintaining its listing on the Nasdaq Stock Market. 180 Life Sciences focuses on developing clinical programs aimed at addressing significant unmet medical needs, particularly through a novel treatment for inflammatory disorders.